Navacaprant
Major Depressive Disorder
Phase 3Active
Key Facts
About Neumora Therapeutics
Neumora Therapeutics is a clinical-stage biotech company founded in 2019 with a mission to revolutionize neuroscience drug development through data-driven precision medicine. Its core strategy involves using a proprietary platform to identify biologically defined patient populations and advance a pipeline of novel, best-in-class therapeutics for major depressive disorder, schizophrenia, Alzheimer's agitation, and Parkinson's disease. The company's lead asset, navacaprant, is a novel kappa opioid receptor antagonist in Phase 3 development for MDD, representing a significant near-term catalyst.
View full company profileTherapeutic Areas
Other Major Depressive Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Accelerated Deep TMS Protocol | BrainsWay | FDA Cleared |
| ZURZUVAE (zuranolone) | Sage Therapeutics | Phase 3 |
| MDD Clinical Trials | Boston Clinical Trials | Not Specified (Typically Phase 2-3) |
| NMDAR Antagonist (GM-2505/Bretisilocin) | Gilgamesh Pharmaceuticals | Phase 2 |
| Neuroplastogen (GM-1020) | Gilgamesh Pharmaceuticals | Phase 2a |
| NA-901 | Biomed | Phase 2B/3 |
| SP-624 (Forvisirvat) | Arrivo BioVentures | Phase 2 |
| NBS System for MDD | Nexstim | Approved |
| NeuroStar for MDD | Neuronetics | Approved |
| Major Depressive Disorder Studies | Noesis Pharma Clinical Trials | Phase 2-4 |
| Depression Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Neurotyping Platform for MDD | Universal Brain | Development |